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Abstract
Background: Frequent somatic mutations have recently been identified in the ras-like domain of the heterotrimeric G
protein a-subunit (GNAQ) in blue naevi 83%, malignant blue naevi (50%) and ocular melanoma of the uvea (46%). The
mutations exclusively affect codon 209 and result in GNAQ constitutive activation which, in turn, acts as a dominant
oncogene.
Methodology: To assess if the mutations are present in other tumor types we performed a systematic mutational profile of
the GNAQ exon 5 in a panel of 922 neoplasms, including glioblastoma, gastrointestinal stromal tumors (GIST), acute myeloid
leukemia (AML), blue naevi, skin melanoma, bladder, breast, colorectal, lung, ovarian, pancreas, and thyroid carcinomas.
Principal Findings: We detected the previously reported mutations in 6/13 (46%) blue naevi. Changes affecting Q209 were
not found in any of the other tumors. Our data indicate that the occurrence of GNAQ mutations display a unique pattern
being present in a subset of melanocytic tumors but not in malignancies of glial, epithelial and stromal origin analyzed in
this study.
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Introduction
Activation of the MAPK signaling pathway plays an important
role in tumorigenesis. Multiple components of this pathway such
as H, N, K-RAS and BRAF are often mutated in human cancer [1].
Most melanocytic neoplasms show oncogenic mutations in
components of the MAPKinase cascade, particularly in BRAF and
NRAS [2]. A recent study has reported frequent somatic mutations
in the heterotrimeric G protein a-subunit (GNAQ) in a subset of
melanocytic neoplasms which do not present alterations in the RAS
or BRAF genes [3]. Genetic, biochemical and biological analysis
has shown that GNAQ behaves as a bona fide human oncogene.
The reported mutations occur exclusively in codon 209 in the ras-
like domain and lead to constitutive activation [3]. The glutamine
at codon 209 of GNAQ corresponding to residue 61 of RAS and is
essential for GTP hydrolysis [3]. It has been previously shown that
in other RAS family members, mutations at this site cause loss of
GTPase activity with constitutive activation [3].
GNAQ encodes for alpha subunit of q class of heterotrimeric
GTP binding protein (Gq) that mediates signals between G-
protein-coupled receptors (GPCRs) and stimulates all four
isoforms of b phospholipase C (PLCb) that catalyzes the
hydrolysis of phosphatidylinositol biphosphate (PIP2). Nearly
40% of GPCRs rely upon Gqa family members to stimulate
inositol lipid signalling. These include more then 50 subtypes of
receptor responsive to a range of hormone, neurotransmitters,
neuropeptides, chemokines, autocrine and paracrine molecules
[4]. The Gq family members, Gq, G11, G14, and G15/16, like
all heterotrimeric G proteins, are composed of three subunits,
Ga,G b and Gc, that cycle between inactive and active signal-
fling states in response to guanine nucleotides. Gqa (GNAQ),
G11a (GNA11), G14a (GNA14) and G15a (GNA15) each have
very different tissue and cell expression patterns. Gqa and G11a
mRNA and protein are ubiquitously distributed across tissues
[4]. Compared with Gqa human, G11a,G 1 4 a,a n dG 1 5 a share
90%, 80%, and 57% amino acid sequence identity, respectively
(Table 1). While GNAQ and GNA11 are ubiquitously expressed,
other members of the family show a very restricted pattern of
expression. For example GNA 15 is confined to tissues rich in
cell types of hematopoietic origin and are enriched in cells in the
earlier stages of differentiation [5]. GNA 14 has been
demonstrated to be expressed mainly in kidney, liver, lung
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equivalent residue to Q209 of GNAQ. We hypothesized that
mutations in GNAQ may also be present in tumor types from
non melanocytic origin where they could represent alternative
route to MAPKinase activation. To assess this hypothesis, we
performed a systematic mutational profile of exon 5 of the
GNAQ gene in a large panel of human tumors from different
tissue types (Table 2). In light of its ubiquitous expression we
also performed the analysis of the GNA11 gene (exon 5) in the
same tumor set.
Table 1. Sequence homology (at the protein level) and expression distribution in human tissues among Gq family genes.
Gqa family member Gqa G11a G14a G15a
Tissue distribution Ubiquitous ubiquitous kidney, liver, lung, pancreas Hematopoietic cells
Sequence homology among different Gqa family members 100% 90% 80% 57%
doi:10.1371/journal.pone.0006833.t001
Table 2. Number of samples analyzed for each histological type and the number of mutations identified.
Tumor type Histotype
Number of samples
analysed
Number of GNAQ
mutated samples P-value Fisher’s exact test)
Blue neavi 13 6
AML 80 0 2,25E-06
Bladder Total 39 0 8,42E-05
transitional cell carcinoma 35 0
cell line 4 0
Breast Total 148 0 7,79E-08
ductal carcinoma 61 0
lobular carcinoma 50 0
medullary carcinoma 18 0
mucinous carcinoma 19 0
Colorectal adenocarcinoma 119 0 2,62E-07
GIST 22 0 1,06E-03
Glioma Total 131 0 1,54E-07
glioblastoma 117 0
anaplastic astrocytoma 2 0
anaplastic oligodendroglioma 2 0
high grade glioma cell lines 14 0
Lung Total 134 0 1,36E-07
adenocarcinoma 110 0
small cell carcinoma 17 0
carcinoid 7 0
Melanoma Total 24 0 7,38E-04
primary 1 0
nodal metastasis 14 0
cutaneous metastasis 7 0
visceral metastasis 2 0
Ovary serous adenocarcinoma 51 0 2,28E-05
Pancreas ductal adenocarcinoma 98 0 7,57E-07
Thyroid Total 63 0 7,85E-06
medullary carcinoma 23 0
papillary carcinoma 20 0
follicular carcinoma 20 0
(AML: acute myeloid leukemia, GIST: Gastrointestinal Stromal Tumors; In addition, p-values of the Fisher’s exact test, used to determine the tissue specificity for
GNAQ
Q209 mutations in blue naevi, are listed.)
doi:10.1371/journal.pone.0006833.t002
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Tumor sample and Ethics Statement
DNA of blue naevi, breast, lung, ovarian and thyroid (papillary
and follicular isotopes carcinoma) cancer samples was obtained
from the Clinical Research Center, Center of Excellence on Aging
at the University-Foundation (Chieti, Italy). Samples were
collected according to the ethical requirements and regulations
of the review board of the Clinical Research Center, University-
Foundation (Chieti, Italy).
DNA of melanoma, colorectal cancer and GIST samples was
obtained from the Department of Experimental Oncology at the
Institute National Tumori (Milan, Italy). Samples were collected
according to the ethical requirements and regulations of the review
board of the Istituto Nationale dei Tumori (Milan, Italy). DNA of
pancreatic adenocarcinoma (PDAC) was obtained from the
Department of Pathology, Section of Anatomic Pathology at the
University of Verona (Verona, Italy). Samples were collected
according to the ethical requirements and regulations of the review
board of the University of Verona (Verona, Italy). Additional
DNA samples of thyroid carcinomas (medullary histotype), were
obtained from the Department of Cellular Biology and Molecular
Pathology at the University of Naples (Naples, Italy). Samples were
collected according to the ethical requirements and regulations of
the review board of the University of Naples (Naples, Italy). DNA
of bladder cancer samples was obtained from the Section of
Experimental Oncology at the Leeds Institute for Molecular
Medicine (Leeds, United Kingdom). Samples were collected
according to the ethical requirements and regulations of the
review board Institute for Molecular Medicine (Leeds, United
Kingdom). Brain cancer samples were obtained from patients
undergoing brain tumor surgery in the Academic Medical Center
(Amsterdam, The Netherlands). Consent for removal of the tissue
and its storage in the tumor bank for research purposes was
obtained and documented in the patient’s medical chart.
Individual consent for this specific project was waivered by the
Academic Medical Center (Amsterdam, The Netherlands) ethics
committee because the research was performed on ‘waste’
material, stored in a coded fashion. The entire tumor database
is described in Table 2.
Isolation of Genomic DNA and mutational analysis
Genomic DNA was isolated as previously described [6]. PCR
primers were designed using Primer 3 (http://frodo.wi.mit.edu/
cgi-bin/primer3/primer3_www.cgi), and synthesized by Invitro-
gen/Life Technologies, Inc. (Paisley, England). A universal
sequencing primer M13 forward, (59-GTAAAACGACGGC-
CAGT-39) was appended to the 59 end used to sequencing
(table 3). PCR products size ranged from 180 to 280 bps.
PCRs were performed in 10-uL reaction volumes in 96-well
format containing 0.25 mmol/L deoxynucleotide triphosphates,
1 umol/L each of the forward and reverse primers, 6% DMSO,
16PCR buffer, 1 ng/uL DNA, and 0.05 unit/uL AmpliTaq Gold
DNA polymerase (Applied Byosystems, Foster City, CA) A
touchdown PCR program was used for PCR amplification (Peltier
Thermocycler, PTC-200, MJ Research, Bio-Rad Laboratories,
Inc., Italy). PCR products were purified using AMPure (Agencourt
Bioscience Corp., Beckman Coulter S.p.A, Milan, Italy). Cycle
sequencing was carried out using BigDye Terminator v3.1 Cycle
Sequencing kit (Applied Biosystems, Foster City, CA) with an
initial denaturation at 97uC for 3 min, followed by 28 cycles of
97uC for 10 s, 50uC for 20 s, and 60uC for 2 min. Sequencing
products were purified using CleanSeq (Agencourt Bioscience,
Beckman Coulter) and analyzed on a 3730 DNA Analyzer, ABI
capillary electrophoresis system (Applied Biosystems). Sequence
traces were analyzed using the Mutation Surveyor software
package (SoftGenetics, State College, PA). Only amplicons
meeting quality criteria were analyzed: tumor samples had Phred
quality scores of $20.
To assess whether these results were statistically significant we
performed the Fisher’s exact test to determine the tissue specificity
for GNAQ mutation in blue naevi tumors as compared to the other
tumor types.
Results and Discussion
We sequenced exon 5 of the GNAQ and GNA11 genes in in a
panel of 922 tumors, including glioblastoma, gastrointestinal
stromal tumors, acute myeloid leukemia, blue naevi, melanoma,
bladder, breast, colorectal, lung, ovarian, pancreas, and thyroid
carcinomas (Table 2). The samples included in the analysis have
been previously used for mutational profiling of cancer genes and
we have shown that common mutations can be identified in this
tumors database [6], [7], [8]. A total of 1844 PCR products,
spanning 423 kb of tumor genomic DNA, were generated and
subjected to direct sequencing. Sequences analysis identified the
presence of the Q209L (c.A627T) mutation in GNAQ in 6/13
(46%) of blue naevi tumors (Figure 1 and Table 2), thus confirming
previous data [3]. Importantly, no mutations of GNAQ exon 5 were
found in any tumor types, other than blue naevi (Table 2).
Similarly, we did not detect mutations in exon 5 of GNA11.
To assess whether these results were statistically significant we
performed the Fisher’s exact test to determine the tissue specificity
for GNAQ mutation in blue naevi tumor as compared to the other
tumor types (Table 2).
Table 3. PCR primers used for the mutational profiling.
Gene Exon Forward Primer Sequence Reverse Primer Sequence
GNAQ 5 59- TTAATATGAGTATTGTTAACCTTGCAG -39 59- M13_CCATTGCCTGTCTAAAGAACAC -39
GNA11 5 59- M13_GCCAGGTGGCTGAGTCCT -39 59- ACTGCACACAGCCCAAGG-39
doi:10.1371/journal.pone.0006833.t003
Figure 1. Example of one of the GNAQ mutations identified in
blue naevi. The arrow indicates the location of the missense change
p.Q209L (c.A627T).
doi:10.1371/journal.pone.0006833.g001
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naevi while at the same time unveils a striking tissue-specific
pattern of the GNAQ
Q209 mutations in human cancer.
Blue naevi arise from intradermal melanocytic proliferations,
which can be congenital or acquired, and present in diverse ways
ranging from discrete bluish moles (blue naevi) to large blue–grey
patches affecting the conjunctiva and periorbital skin (naevus of
Ota), shoulders (naevus of Ito) and the lower back (Mongolian
spot) [3]. Uveal melanomas are thought to originate from
melanocytes within the choroidal plexus of the eye and are
distinct from cutaneous melanoma by characteristic cytogenetic
alterations. Of note, a potential connection between intradermal
melanocytic neoplasms and uveal melanoma is suggested by the
fact that naevus of Ota is a risk factor for uveal melanoma [3].
Oncogenic alterations in the RAS and BRAF genes are known to
frequently affect cutaneous melanoma. Until the discovery of the
GNAQ
Q209 mutations there were no oncogenes altered at high
frequency in uveal melanomas and blue naevi. The tissue-
specificity of GNAQ mutations may be linked to its involvement
in endothelin signaling, which is important for development of
melanocytes and also is required for the migration of melanoblasts
[5]. The canonical downstream signaling pathways of GNAQ are
the b-isoforms of phospholipase C (PLC-b). Gqa, G11a, bind and
stimulate PLC-b enzymes to initiate inositol lipid signalling. PLC-
b enzymes catalyze the hydrolysis of the phospholipid phospha-
tidylinositol bisphosphate, (PIP2), to release inositol trisphosphate
(IP3) and diacylglycerol (DAG). These second messengers
propagate and amplify the Ga-mediated signal trough stimulation
of protein kinase C (PKC). [3] One hypothesis is that GNAQ
regulates cell growth through a RAS dependent or RAS-
independent signaling mechanism involving the PKC-dependent
ERK pathway. [9]. Functional assays are now required to assess
this possibility and to understand in details the oncogenic signaling
mechanisms regulated by GNAQ mutant alleles. Targeting either
the mutated GNAQ
Q209 protein or the oncogenic signaling pathway
controlled by mutated GNAQ may open up new therapeutic
strategies for melanocytic tumors.
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